What Affects the Quality of Pharmacovigilance? Insights From Qualitative Comparative Analysis

被引:0
作者
Wang, Yadong [1 ]
Chen, Yue [1 ]
Xu, Xingjuan [1 ]
Ying, Ting [1 ]
Xia, Runan [1 ]
Zhang, Yuanyuan [1 ,2 ]
Xie, Xuefeng [1 ,3 ]
机构
[1] Anhui Med Univ, Sch Pharm, Hefei, Anhui Province, Peoples R China
[2] Anhui Med Univ, Key Lab Publ Hlth Social Governance Philosophy & S, Hefei, Anhui, Peoples R China
[3] Anhui Med Univ, Inflammat & Immune Mediated Dis Lab Anhui Prov, Hefei, Anhui Province, Peoples R China
关键词
crisp-set qualitative comparative analysis; marketing authorization holder; pharmacovigilance;
D O I
10.1002/prp2.70102
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Pharmacovigilance plays a significant role in guaranteeing the safety of medications for patients. Over the last three decades, China has significantly advanced its pharmacovigilance practices, yet the factors that drive the quality of pharmacovigilance remain unclear. This study aimed to investigate how multiple factors interactively influence the quality of pharmacovigilance and identify pathways for achieving high-quality pharmacovigilance practices. A unique sample of pharmacovigilance-specific inspection reports from 13 representative companies in China was adopted in analysis. Given the qualitative nature of the inspection reports, we utilized crisp-set qualitative comparative analysis (csQCA) with five factors structure based on the technology-organization-environment (TOE) theoretical framework. The csQCA enabled us to elucidate the interactions among the antecedents of pharmacovigilance quality through quantitative univariate necessity analysis and configuration analysis. Three pathways contributing to high-quality pharmacovigilance were identified, and "Dedicated and Qualified Person for Pharmacovigilance (DQPPV)" was shown to be involved in all three pathways. Upon examining the manner in which multiple variables influence the quality of pharmacovigilance, it becomes evident that the DQPPV represents a factor that warrants further investigation. The results of the configuration allow companies to implement targeted measures to enhance the functionality of the pharmacovigilance system and to improve the quality of the system. Further research could explore the influence of additional factors on pharmacovigilance efforts, which could then contribute to marketing authorization holders' (MAHs') pharmacovigilance efforts.
引用
收藏
页数:8
相关论文
共 37 条
[1]  
[Anonymous], Good pharmacovigilance practices |
[2]  
[Anonymous], National Adverse Drug Reaction Monitoring Annual Report (2017),
[3]  
[Anonymous], 1973, Handbook of resolutions and decisions of the World Health Assembly and the Executive Board. v. 1: cumulative definitive ed.
[4]  
v. 2: cumulative definitive ed.
[5]  
v. 3, V3rd
[6]  
[Anonymous], Medicinal Product Administration Law of the People's Republic of China,
[7]   Pharmacovigilance: An Overview [J].
Beninger, Paul .
CLINICAL THERAPEUTICS, 2018, 40 (12) :1991-2004
[8]  
Bergner D, 2009, CH CRC DATA MIN KNOW, P19
[9]   A set-theoretic approach to organizational configurations [J].
Fiss, Peer C. .
ACADEMY OF MANAGEMENT REVIEW, 2007, 32 (04) :1180-1198
[10]   BUILDING BETTER CAUSAL THEORIES: A FUZZY SET APPROACH TO TYPOLOGIES IN ORGANIZATION RESEARCH [J].
Fiss, Peer C. .
ACADEMY OF MANAGEMENT JOURNAL, 2011, 54 (02) :393-420